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RIP4 Regulates Epidermal Differentiation and
Cutaneous Inflammation
Ryan B. Rountree1,4, Cynthia R. Willis2, Huyen Dinh2, Hal Blumberg2,5, Keith Bailey3, Charles Dean Jr3,
Jacques J. Peschon2,6 and Pamela M. Holland1
The receptor-interacting protein (RIP) family kinase RIP4 interacts with protein kinase C (PKC) isoforms and is
implicated in PKC-dependent signaling pathways. RIP4/ mice die at birth with epidermal differentiation
defects, causing fusions of all external orifices and loss of the esophageal lumen. To further understand RIP4
function in the skin, we generated transgenic mice with epidermal-specific expression of RIP4 using the human
keratin-14 promoter (K14-RIP4). The K14-RIP4 transgene rescued the epidermal phenotype of RIP4/ mice,
showing that RIP4 acts autonomously in the epidermis to regulate differentiation. Although RIP4/ mice share
many phenotypic similarities with inhibitor kB kinase (IKK)a/ mice and stratifin repeated epilation (SfnEr/Er)
mice, the K14-RIP4 transgene failed to promote epidermal differentiation in these mutant backgrounds.
Unexpectedly, topical treatment of K14-RIP4 mice with 12-O-tetradecanoylphorbol-13-acetate (TPA) induced
dramatic, neutrophilic inflammation, an effect that was independent of tumor necrosis factor type 1 receptor
(TNFR1/p55) function. Despite their enhanced sensitivity to TPA, K14-RIP4 mice did not have an altered
frequency of tumor formation in TPA-promoted skin cancer initiated with 7,12-dimethylbenz[a]anthracene
(DMBA). These data suggest that RIP4 functions in the epidermis through PKC-specific signaling pathways to
regulate differentiation and inflammation.
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INTRODUCTION
The RIP family members RIP1–RIP7 are a diverse group of
proteins that share homology within their serine/threonine
kinase domain. Individual members differ by the types of
domains linked to their kinase region, and are involved
various cellular processes such as cell death, immunity,
response to DNA damage, and differentiation (Meylan and
Tschopp, 2005).
RIP4 was initially described as a previously unidentified
protein found to interact with protein kinase C (PKC)bI and
PKCd in yeast two-hybrid assays (Bahr et al., 2000; Chen
et al., 2001). RIP4 contains an N-terminal kinase domain
linked to a unique intermediate domain that can be cleaved
by caspases, and a C terminus domain harboring ankyrin
repeats that may negatively regulate its activity (Meylan et al.,
2002). Other groups have reported that overexpression of
RIP4 in HEK293T cells activates nuclear factor-kB (NF-kB),
c-Jun N-terminal kinase (JNK), and activator protein-1. They
also indicate that catalytically inactive versions of RIP4
specifically inhibit signaling induced by 12-O-tetradecanoyl-
phorbol-13-acetate (TPA)/Ca2þ ionophore, suggesting that
RIP4 may function primarily in a PKC-dependent signaling
pathway (Meylan et al., 2002; Muto et al., 2002; Moran et al.,
2003).
RIP4/ mice die at birth and have fewer skin folds than
wild-type littermates, partial fusion of the hind limbs and tail
to the body, and fusion of the external orifices, oral cavity,
and esophagus. The epidermis of RIP4/ mice is thickened
with expanded spinous and granular layers, and contains an
outermost layer of parakeratotic cells instead of enucleated
squamous cells. Furthermore, proteins that characteristically
mark specific layers of the epidermis are mis-expressed
(Holland et al., 2002). Although the phenotype of RIP4/
animals appears to result from defects restricted to the
squamous epithelium, the expression of RIP4 mRNA in adult
tissues is widespread (Chen et al., 2001). Therefore, it is
unclear whether RIP4 functions outside of the epidermal
compartment, as this may have been masked by the severity
of the epidermal phenotype.
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The phenotypes of RIP4/ animals are remarkably similar
to two other mouse mutants, inhibitor kB kinase (IKK)a/
and stratifin repeated epilation (SfnEr/Er) mice, which also die
at birth with fusion of external orifices and a thickened
epidermis (Hu et al., 1999; Li et al., 1999, 2005; Takeda
et al., 1999; Fisher, 2000; Holland et al., 2002; Herron et al.,
2005). Similar to RIP4/ mutants, the epidermis of IKKa/
and SfnEr/Er mice has an expanded spinous layer and an
outermost layer containing parakeratotic cells. However, the
epidermis from RIP4/ and SfnEr/Er animals express markers
of more differentiated epidermal layers, such as filaggrin,
whereas the epidermis of IKKa/ mice does not. IKKa/
and SfnEr/Er mice also have dramatic alterations in limb
development that are not observed in RIP4/ mice.
Interestingly, epidermal-specific expression of IKKa from the
human keratin-14 promoter is sufficient to restore both
epidermal differentiation and limb development in IKKa/
mice (Sil et al., 2004).
The epidermal phenotypes of these mutants suggest that
RIP4, IKKa, and Sfn function in either shared or independent
pathways to promote epidermal differentiation. Stratifin
protein has been biochemically purified as an enhancer of
PKC activity in vitro, but it can bind many different proteins
and has a wide variety of other functions attributed to it
(Dellambra et al., 1995; Laronga et al., 2000; Benzinger
et al., 2005; Yang et al., 2006; Wilker et al., 2007). The
function of IKKa in epidermal differentiation is independent
of its role in NF-kB regulation (Hu et al., 2001; Descargues
et al., 2008). Because blocking NF-kB signaling results in
hyperplastic epidermal development without preventing
differentiation (Seitz et al., 1998; Zhang et al., 2004), it is
likely that RIP4 has NF-kB-independent functions as well.
Because RIP4 is necessary for normal epidermal differ-
entiation, we focused our studies on the function of RIP4 in
the skin. Using a K14-RIP4 transgene, we showed that RIP4
functions autonomously in the epidermis to regulate differ-
entiation. Interestingly, K14-RIP4 mice are hypersensitive to
inflammation induced by topical application of TPA, but
have a normal inflammatory response in a TPA-independent
model of contact hypersensitivity. In a 7,12-dimethylben-
z[a]anthracene (DMBA)/TPA model of skin cancer, K14-RIP4
mice develop elevated inflammation and increased epider-
mal hyperplasia, yet do not show altered rates of tumor
formation. In total, these studies suggest that RIP4 functions in
PKC-dependent signaling pathways to regulate epidermal
differentiation and cutaneous inflammation.
RESULTS
RIP4 expression is required within the epidermis for normal
differentiation
To examine the functions of RIP4 in the epidermis, we
generated transgenic mice using an RIP4 expression construct
driven by the human keratin-14 promoter (K14-RIP4). Two
independent lines were established, and the relative expres-
sion of the transgenes was determined from the adult tail skin
cDNA using TaqMan PCR of a transgene-specific tag.
Compared with endogenous RIP4 mRNA levels in the skin,
the higher expressing line produced 15-fold more RIP4
encoding mRNA than did wild-type mice and was used in
further experiments. The lower expressing line produced RIP4
encoding mRNA similar to wild-type levels (data not shown).
On the C57BL/6 background, neither line exhibited any overt
phenotype, and the mice were viable and fertile (data not
shown). Expression of the transgene in the epidermis was
confirmed using immunohistochemistry on sectioned E18.5
mouse embryos. Although the expression of endogenous
RIP4 protein was undetectable, transgenic animals had clear
expression of RIP4 primarily in the spinous layer of the
epidermis (Figure 1a). No expression of RIP4 was observed in
non-epidermal tissues (data not shown).
We next tested whether RIP4 expression was required only
within the epidermis for differentiation by crossing the K14-
RIP4 transgenic mice onto the RIP4/ background (desig-
nated as K14-RIP4; RIP4/). In contrast to RIP4/ animals
that died immediately after birth with fusions of all external
orifices, K14-RIP4; RIP4/ animals derived from either
transgenic line developed with open mouths, nostrils, and
anuses (Figure 1b). Furthermore, the epidermis from these
mice was cornified and expressed differentiation markers in
normal domains (Figure 1c–g). Postnatal K14-RIP4; RIP4/
mice died within 2 days of birth, apparently due to a failure of
the K14-RIP4 transgene to rescue the esophageal fusion
present in RIP4/ animals (Figure 1i). This correlated with a
41,000-fold less transgene expression in the adult esophagus
compared with that in skin (data not shown), in agreement
with previous data using a similar K-14 promoter (Sil et al.,
2004). These results show that RIP4 is required autonomously
in the epidermis for differentiation.
K14-RIP4 does not alter epidermal differentiation in IKKa/ or
SfnEr/Er mice
IKKa/ and SfnEr/Er mice form a poorly differentiated
epidermis that resembles the epidermis of RIP4/ animals,
but it is unclear whether RIP4, IKKa, and stratifin function in
the same or different pathways to regulate epidermal
differentiation (Hu et al., 1999, 2001; Li et al., 1999, 2005;
Takeda et al., 1999; Holland et al., 2002; Herron et al.,
2005). To determine whether RIP4 regulated the expression
of IKKa or stratifin, we examined the expression of these
proteins in RIP4/ mice by immunohistochemistry. In
control and RIP4/ skin, stratifin protein was detected
throughout the epidermis (Figure 1h). IKKa protein was not
detected strongly enough to characterize its expression
pattern in the skin, but by microarray analysis, IKKa and
stratifin mRNA expression levels were found to change o3
fold in the skin from control and RIP4/ mice (data not
shown; Holland et al., 2002). These analyses indicate that
RIP4 is not required for the expression of IKKa or stratifin
gene products.
In an attempt to alleviate the block in the epidermal
differentiation of IKKa/ or SfnEr/Er mutants, we crossed the
higher expressing line of K14-RIP4 mice onto these mutant
backgrounds (designated K14-RIP4; IKKa/ or K14-RIP4;
SfnEr/Er). At E18.5, K14-RIP4; IKKa/ and K14-RIP4; SfnEr/Er
mice developed oral, limb, and tail epithelial fusions and
appeared phenotypically indistinguishable from mutants
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lacking the K14-RIP4 transgene (Figure 2a and h, and data not
shown). The epidermis of K14-RIP4; IKKa/ animals was
thickened, lacked granular and cornified layers, and had no
indication of altered differentiation in comparison with the
IKKa/ epidermis (Figure 2b–g). Similarly, the epidermis of
K14-RIP4; SfnEr/Er embryos was phenotypically comparable
with that of SfnEr/Er mutants (Figure 2i–n). In both mutant
backgrounds, immunohistochemical staining verified that
exogenous RIP4 protein was dramatically upregulated in
K14-RIP4; IKKa/ and K14-RIP4; SfnEr/Er mice compared
with that in IKKa/ and SfnEr/Er mice (Figure 2c and j). These
data show that elevating RIP4 expression is not sufficient to
promote epidermal differentiation in IKKa/ or SfnEr/Er mice.
K14-RIP4 mice are specifically sensitive to TPA-driven,
TNFR1-independent inflammation
Other research suggests that RIP4 functions to transduce TPA-
initiated signaling cascades (Meylan et al., 2002; Muto et al.,
2002; Moran et al., 2003). This raised the question of whether
K14-RIP4 mice would show altered sensitivity in a model of
TPA-induced inflammation. TPA was applied to the ears of
K14-RIP4 mice from the higher expressing line and wild-type
littermates for 3 consecutive days, and ear thickness was
measured. Strikingly, the transgenic mice showed a marked
increase in inflammation characterized by erythema, edema,
and surface crusting (Figure 3a and b). This correlated with a
dramatic and prolonged increase in the ear thickness of
transgenic mice that was clearly distinct from that of control
animals (Figure 3e, Po0.0001). Vehicle-treated ears of either
genotype had no detectable inflammation (Figure 3c and d
and data not shown).
Histological examination of the TPA-treated ears in
transgenic mice showed that the inflammation consisted
predominantly of neutrophils. By day 3, neutrophils infil-
trated the epidermis and ranged from intracorneal pustules to
full-thickness involvement of the epidermis and the super-
ficial dermis. On day 7, the inflammation was more
extensive, with corresponding necrosis and ulceration of
the epidermis. After 24 days, inflammation consisted of a
mixed population of mononuclear cells in the dermis with
associated fibrosis and reactive hyperplasia of the overlying,
intact epidermis (Figure 3g). At 17 weeks post treatment, the
examination of ears from K14-RIP4 mice showed no
indication of inflammation, although dermal fibrosis and
epidermal thickening typical of scarred tissue was present
(data not shown). In contrast, inflammation in the control ears
on days 3 and 7 was mild, and was characterized by a
mixture of neutrophils and mononuclear cells. By day 24, the
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Figure 1. A K14-RIP4 transgene rescues the epithelial defects in RIP4/
animals. (a) Immunohistochemistry of RIP4 protein in sectioned E18.5
embryos detected RIP4 only in the epidermis of K14-RIP4 transgenic mice
(right panel). (b) The taut skin and oral fusions present in E18.5 RIP4/ mice
(center panel) are rescued in K14-RIP4; RIP4/ animals (right panel).
Sections of E18.5 skin stained with (c) H&E, or immunohistochemistry
detecting (d) keratin-14 (K14), (e) keratin-1 (K1), (f) involucrin, (g) keratin-6
(K6), and (h) stratifin show a normal epidermal architecture and protein
expression in K14-RIP4; RIP4/ skin (right column) compared with that in
RIP4/ (center column) or control RIP4þ / skin (left column). (i) H&E-stained
sections reveal that esophageal fusions typical of RIP4/ embryos (center
panel) are also present in K14-RIP4; RIP4/ embryos. An animal with the
K14-RIP4 transgene from the higher expressing line is shown in panel a, and
animals from a cross with the lower expressing line are shown in panels b–i.
Bars¼ 100 mm (a and c–h); or 50 mm (i).
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inflammation was resolved and the ears appeared normal
(Figure 3f).
Skin inflammation, whether induced by phorbol esters or
spontaneously occurring in transgenic or null mutant mice,
is often dependent on the activity of tumor necrosis factor
type 1 receptor (TNFR1)/p55 (Kondo and Sauder, 1997;
Pasparakis et al., 2002; Lind et al., 2004). In addition, TNF
signaling through TNFR1/p55 has a critical role in the patho-
genesis of human skin inflammatory disease (Bradley, 2008).
We therefore crossed the higher expressing line of K14-RIP4
mice onto the p55/ background and tested them in the
TPA-driven model of inflammation. As the TNFR1/p55
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Figure 2. Overexpression of RIP4 fails to rescue epidermal differentiation in IKKa/ or SfnEr/Er animals. (a) E18.5 whole mount or sectioned embryos
showing that the taut skin, oral fusions, truncated limbs, and undifferentiated epidermis characteristic of IKKa/ (a–g, center panel) or SfnEr/Er mice
(h–n, center panel) are unaltered in K14-RIP4; IKKa/ (a–g, right panel) or K14-RIP4; SfnEr/Er mice (h–n, right panel). Sections were stained with H&E (b and i),
or immunohistochemistry to detect the following proteins: (c and j) RIP4, (d and k) keratin-14 (K14), (e and l) keratin-1 (K1), (f and m) involucrin, and
(g and n) stratifin. RIP4 expression is present throughout the epidermis of (c) K14-RIP4; IKKa/ and (j) K14-RIP4: SfnEr/Er embryos. Bars¼ 50 mm.
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Figure 3. TPA induces neutrophilic inflammation in K14-RIP4 transgenic mice. Right ears from (a) wild-type (WT) or (b) K14-RIP4 mice over 24 days after
topical TPA application (days 1–3) in a model of inflammation. The ears of K14-RIP4 mice show increased edema, surface crusting, and scarring compared
with those of wild-type mice. (c and d) The left, vehicle control ears of mice shown in panels a and b, respectively. (e) Thickness of either TPA- or ethanol
(vehicle control)-treated ears measured over 24 days (n¼5 animals per genotype; thickness is plotted as mean±SEM). (f) H&E-stained sections of TPA-treated
ears from WT mice show a mild infiltration of cells at day 3, which declines by day 7 and is completely resolved by day 24. (g) H&E-stained sections of
TPA-treated ears from K14-RIP4 transgenic mice showing full-thickness epidermal infiltration of neutrophils on day 3, an intracorneal pustule of neutrophils
on day 7, and a mild dermal infiltrate and hyperplastic epidermis on day 24. Bars¼ 50 mm.
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receptor is the dominant mediator of TNFa-induced skin
inflammation, we did not generate additional crosses with
either TNFa/ or TNFR2/p75/ mice (Kondo and Sauder,
1997). The ears of K14-RIP4; p55/ mice were thickened
and contained infiltrating neutrophils, similar to the ears of
K14-RIP4; p55þ / littermates (Figure 4a and b). Similarly, the
average ear thickness of K14-RIP4; p55/ mice was not
significantly different from that of K14-RIP4; p55þ / mice
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Figure 4. K14-RIP4 mice are specifically sensitive to TPA-driven, TNFR1/p55-independent inflammation. (a) Thickness of TPA-treated ears from p55þ /,
K14-RIP4; p55þ /, or K14-RIP4; p55/ mice as measured over 10 days (days 1–3, n¼7 animals per genotype; days 4–7, n¼5; thickness is plotted as
mean±SEM). (b) H&E-stained sections of TPA-treated ears from K14-RIP4; p55þ / or K14-RIP4; p55/mice. Neutrophils can be seen infiltrating the epidermis
on day 3, and by day 7, regions of the skin are ulcerated with overlying neutrophils. (c) Thickness of DNFB- or vehicle-treated ears from mice in a model
of contact hypersensitivity (n¼ at least 11 animals per genotype for each time point; overall, P¼0.624 for wild-type versus K14-RIP4 DNFB-treated ears).
(d) H&E-stained sections of ears on 1 or 7 days after challenge with DNFB. Note similar amounts of infiltrating cells in wild-type and K14-RIP4 transgenic ears,
and lack of epidermal involvement. Bars¼ 50mm.
www.jidonline.org 107
RB Rountree et al.
Evaluating RIP4 Function in the Skin
(P¼0.632), although both groups were significantly different
from p55þ / mice (Po0.0001). These data indicate that the
excessive inflammation induced by TPA in K14-RIP4 mice is
not dependent on TNFR1 function.
We next tested the higher expressing line of K14-RIP4
mice in a DNFB-induced model of contact hypersensitivity.
This model produces a TH1-dependent reaction in response
to the production of pro-inflammatory cytokines by immune
cells and keratinocytes (Wang et al., 2003). Interestingly,
K14-RIP4 transgenic mice were no different from control
mice with regard to the magnitude of inflammation in this
model, and showed no bias toward a neutrophilic infiltrate
(Figure 4c and d). In total, these data show that the K14-RIP4
mice are specifically sensitive to TPA-triggered inflammation,
and that this inflammation occurs independent of TNFR1
function.
Transgenic mice overexpressing PKCa in the skin also
develop neutrophilic inflammation that is TNFR1-indepen-
dent (Cataisson et al., 2005). To assess whether RIP4
regulates the expression or activity of PKC isoforms, we
stimulated primary keratinocytes derived from wild-type,
RIP4/, or K14-RIP4 animals with TPA and examined
extracts of these cells by western blot analysis. Multiple
PKC and phospho-PKC isoforms were tested, including PKCa
and PKCd. No difference was detected in the expression level
or phosphorylation kinetics of PKC isoforms in TPA-stimu-
lated mutant, transgenic, or control keratinocytes (data not
shown). Similarly, TPA-induced phosphorylation of the
MARCKS protein, a general target of multiple PKC isoforms,
was unaffected by the genotype of RIP4 (data not shown).
Conditioned media from TPA-treated wild-type and K14-RIP4
keratinocytes were also collected and analyzed for cytokine/
chemokine profiling (Rules Based Medicine, Charles River
Laboratories), but no reproducible differences were found
between the two genotypes (data not shown). These findings
are still consistent with RIP4 functioning downstream of PKC
during signal transduction, but further studies are required to
determine this definitively.
K14-RIP4 mice spontaneously develop inflammation, but do
not have an altered rate of skin cancer with treatment of DMBA
and TPA
TPA application and inflammation are factors known to
promote tumorigenesis in the skin (Mueller, 2006). As the
K14-RIP4 mice were more sensitive to TPA-induced inflam-
mation, we tested whether they would have an altered
incidence of papilloma or squamous cell carcinoma forma-
tion in a DMBA/TPA skin cancer model. Because the C57BL/
6 background of the K14-RIP4 mice used above is resistant to
carcinogenesis in this model, we first bred the higher
expressing K14-RIP4 line onto the more sensitive FVB/N
background (Hennings et al., 1993). It can be noted that K14-
RIP4 mice on the FVB/N background spontaneously devel-
oped ringtail or inflamed tails (23 of 43, or 54%, of mice aged
4–13 months old) and/or inflamed ears (11 of 43, or 26%,
Figure 5a) beginning atB3 months of age. These phenotypes
were associated with a mixed lymphocytic and neutrophilic
infiltrate, epidermal hyperplasia, and mild hyperkeratosis in
some affected tails (data not shown). These responses are
another indication that elevated RIP4 expression promotes
inflammation in the skin and further suggest the presence of
strain-specific genetic modifiers of RIP4 activity.
We next enrolled 7- to 8-week-old K14-RIP4 and control
mice into a DMBA/TPA skin cancer model using a single
application of 25 mg of DMBA, followed by 5 mg of TPA twice
per week for 20 weeks. No difference in the development of
papillomas, squamous cell carcinomas, or metastases was
found between transgenic and control mice (data not shown).
However, 2 weeks after TPA treatment, the skin of transgenic
mice became reddened and showed signs of hair loss (Figure
5b). To further characterize this phenotype, a separate group
of mice was treated bi-weekly with TPA for 2 weeks and skin
samples were collected 18 hours after the last treatment.
Histology of sectioned skin showed that the K14-RIP4 mice
developed an increased number of intracorneal pustules,
primarily associated with hair follicles (Figure 5c, wild-type:
0.59±0.12 pustules per cm, n¼ 6; K14-RIP4: 2.61±0.34
pustules per cm, n¼ 6; P¼ 0.0022). Mice in the cancer
model were also examined after 14 weeks of TPA treatment,
with or without initiation by DMBA. At this time point,
inflammation in the epidermis, dermis, and associated with
the papillomas was comparable between K14-RIP4 and
control mice, and the epidermis from both groups contained
occasional pustules. However, the transgenic mice showed
a slightly more pronounced epidermal hyperplasia with a
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Figure 5. Spontaneous inflammation and increased sensitivity to TPA in
FVB/N K14-RIP4 mice. (a) Examples of adult K14-RIP4 mice on the FVB/N
genetic background that spontaneously developed tail or ear inflammation
(mice aged 4 months (top left), 10 months (bottom left), and 7 months (right).
(b) Shaved backs of wild-type (WT) or K14-RIP4 mice in the DMBA/TPA
skin cancer model after 2 weeks of twice weekly TPA application. K14-RIP4
animals have reddened skin and patchy hair loss. (c) H&E-stained sections
from WT and transgenic mice showing intracorneal pustules in K14-RIP4
mice after 2 weeks of TPA treatment and the hyperplastic epidermis in
K14-RIP4 mice after 14 weeks of TPA treatment. Bars¼50 mm.
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prominent granular layer (Figure 5c, average hyperplasia
score for wild-type: 2.0±0.0, n¼8; K14-RIP4: 2.9±0.1,
n¼8; P¼0.0014). These data indicate that chronic TPA
application to the skin of K14-RIP4 mice leads to enhanced
epidermal inflammation and hyperplasia. However, elevated
RIP4 expression in the epidermis does not alter the onset,
growth, or progression of skin cancer in this model.
DISCUSSION
Here, we show that RIP4 expression in the epidermis is
sufficient to promote epidermal differentiation in RIP4-
deficient mice. Furthermore, to the best of our knowledge,
we provide the first evidence for a role of RIP4 in cutaneous
inflammation. These findings extend previous work that
identified skin as the primary tissue requiring RIP4 for normal
development (Holland et al., 2002). The specific sensitivity of
K14-RIP4 transgenic mice to TPA-driven inflammation also
supports previous studies, suggesting that RIP4 functions
primarily in PKC-dependent signaling pathways (Meylan
et al., 2002; Muto et al., 2002; Moran et al., 2003).
PKC activation in keratinocytes leads to many events
critical for differentiation, such as cell-cycle exit, expression
of components found in the granular layer and cornified
envelope, and apoptosis. Several PKC isoforms are expressed
in the epidermis, including the classical isoform PKCa, the
novel isoforms PKCd, PKCe, PKCZ, and the atypical isoforms
PKCz and PKCi (Denning, 2004; Helfrich et al., 2007).
However, none of the reported null mutant mice lacking
individual PKC isoforms develop defects in epidermal
differentiation (Castrillo et al., 2001; Leitges et al., 2001a, b,
2002; Chida et al., 2003; Hara et al., 2005). The reason for
this may be functional redundancy between isoforms that
compensate when only one is lacking. Our finding that a
K14-RIP4 transgene can rescue epidermal differentiation in
RIP4-deficient mice indicates that RIP4 functions within
keratinocytes to promote differentiation. Furthermore, RIP4
has been shown to interact with classical (PKCbI) and novel
(PKCd) isoforms of PKC (Bahr et al., 2000; Chen et al., 2001).
Therefore, an intriguing possibility is that RIP4 interacts with
multiple PKC isoforms in keratinocytes to integrate or
promote PKC signaling. A critical test of this model will be
to identify proteins that interact with RIP4 in vivo. Also, the
generation of compound mutants that lack multiple PKC
isoforms in the epidermis may lead to phenotypic abnorm-
alities that resemble RIP4/ animals.
Endogenous RIP4 protein is undetectable by our immu-
nohistochemistry protocol in wild-type embryos, but expres-
sion is clearly visible in the skin of K14-RIP4 transgenics.
Surprisingly, the human K14 promoter we used typically
targets gene expression to the basal layer of the epidermis
(Vassar et al., 1989; Sil et al., 2004; Hirakawa et al., 2005),
but K14-RIP4 expression is found primarily in the spinous
layer (Figures 1a, 2c and j). This finding may imply that RIP4
protein functions most actively in the spinous layer during
epidermal differentiation, where it is regulated by a mechan-
ism that increases its translation rate or stability in the spinous
layer. This layer has been noted for its expression of PKCa
(the only classical isoform expressed in the epidermis) and
PKCd (Denning, 2004), and highlights these two isoforms as
potential RIP4 interaction partners in vivo.
Although the K14-RIP4 transgene produces high levels of
RIP4 protein and can rescue epidermal differentiation in
RIP4/ animals, it is unable to promote epidermal differ-
entiation in stratifin- or IKKa-deficient mice. Progress is being
made on identifying the signaling pathways involving these
proteins, but much is still unknown (Wynshaw-Boris, 2007;
Descargues et al., 2008). If RIP4, stratifin, and IKKa function
in the same pathway to promote skin differentiation, then this
could indicate that RIP4 functions upstream of IKKa and
stratifin. This interpretation is supported by the observation
that RIP4 activation of NF-kB requires IKKb function (Meylan
et al., 2002). Alternatively, RIP4, stratifin, and/or IKKa could
function in independent pathways. This would explain the
phenotypic differences between the respective mutants
(Fisher, 2000; Holland et al., 2002). It is also consistent with
the findings that epidermal differentiation can be rescued by
grafting IKKa/ skin onto IKKaþ /þ hosts, but not by grafting
RIP4/ skin onto RIP4þ /þ hosts (Hu et al., 2001; Holland
et al., 2002). Finally, it is possible that RIP4 can drive
epidermal differentiation in IKKa/ or SfnEr/Er animals, but
simply elevating RIP4 expression is not sufficient to activate
the necessary signaling events. Therefore, our experiments do
not exclude the possibilities that forced stimulation of RIP4-
specific signaling pathways, or the expression of a constitu-
tively active version RIP4, could promote differentiation on
these mutant backgrounds.
Challenging K14-RIP4 mice with topically applied TPA
leads to a striking infiltration of neutrophils. Similar studies
have also been carried out in transgenic mice overexpressing
specific PKC isoforms in the epidermis with keratin-14 or
keratin-5 promoters. Of the isoforms that have been tested,
only PKCa transgenic mice develop a neutrophilic inflam-
matory response after TPA application (Reddig et al., 1999,
2000; Wang and Smart, 1999; Jansen et al., 2001; Cataisson
et al., 2003). This treatment leads to the formation of
intracorneal pustules at hair follicles that appear remarkably
similar to those of K14-RIP4 animals (Figure 5c). Furthermore,
the neutrophilic inflammation of both K14-RIP4 and K5-PKCa
animals is TNFR1-independent (Cataisson et al., 2005). These
results may indicate that RIP4 functions downstream of PKCa
to promote epidermal inflammation. We found that the
expression level and phosphorylation of PKCa and other PKC
isoforms were similar between keratinocytes derived from
C57BL/6 wild-type, RIP4/ or K14-RIP4 mice (data not
shown). This result is consistent with a model in which RIP4
signals downstream of PKCa. Inhibition of PKCa reduces
expression of differentiation markers in keratinocytes stimu-
lated to differentiate in response to calcium (Lee et al., 1997;
Yang et al., 2003). Therefore, it is also a strong candidate for
an interacting partner with RIP4 during epidermal differentia-
tion. PKCa/ mice have been reported (Leitges et al., 2002;
Hara et al., 2005), and it would be interesting to test how
K14-RIP4 transgenic mice respond to TPA on a PKCa-
deficient background.
In PKCa transgenic mice, a single topical treatment with
TPA is sufficient to mediate epidermal inflammation. In
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addition, TPA stimulation of keratinocytes from PKCa
transgenic mice leads to excessive elevation of mRNA or
protein levels of several cytokines and chemotactic factors,
including TNF-a and macrophage inflammatory protein-2
(Wang and Smart, 1999; Cataisson et al., 2003, 2005, 2006).
In contrast, it requires at least two TPA applications for
K14-RIP4 mice on the C57BL/6 background to develop a
neutrophilic infiltrate similar to that seen with one TPA
application in PKCa transgenic mice (data not shown).
Furthermore, no consistent changes in cytokines or chemo-
tactic factors were detected in conditioned media from TPA-
treated C57BL/6 K14-RIP4 keratinocytes compared with
wild-type (data not shown). The differences between these
transgenic strains could suggest that other factors downstream
of PKCa in addition to RIP4 contribute to epidermal
inflammation. Alternatively, because PKCa is directly bound
and activated by TPA, perhaps increasing the levels of PKCa
is more effective at initiating a TPA-driven signal than
elevating RIP4 expression in the presence of normal levels
of PKCa. It is possible that on the FVB/N background, which
is known to have an enhanced sensitivity to TPA over C57BL/
6 mice (Hennings et al., 1993) and on which K14-RIP4 mice
showed spontaneous inflammation (Figure 5a and b), TPA
stimulation might result in a clearer enhancement of cytokine
production in K14-RIP4 keratinocytes.
Inflammation is believed to be an important promoting
factor in the DMBA/TPA skin cancer model and other cancers
(Balkwill et al., 2005; Mueller, 2006). Therefore, we were
surprised to find that K14-RIP4 transgenic mice in a DMBA/
TPA model developed exacerbated inflammation without an
increased rate of carcinogenesis. This discrepancy may be
due to the relatively high dose of DMBA and TPA used in our
experiments. Although similar regimens have shown strong
differences in transgenic mouse strains overexpressing PKC
isoforms in the skin, they did not alter carcinogenesis in K14-
PKCa or K5-PKCa transgenic mice (Reddig et al., 1999, 2000;
Wang and Smart, 1999; Jansen et al., 2001). However, later
experiments showed that K5-PKCa transgenic mice were
indeed more susceptible to DMBA/TPA cancer promotion
when a suboptimal dose of TPA was used (Cataisson et al.,
2009). We have not attempted to characterize K14-RIP4 mice
using a suboptimal cancer promotion model, but this could
reveal an increased sensitivity that has been masked by our
protocol.
In conclusion, our study shows that RIP4 functions in the
epidermis to regulate differentiation, potentially through
PKC-dependent signaling cascades. This work also identifies
a previously unknown activity of RIP4 in promoting
cutaneous inflammation. In the future, it will be important
to gain a better understanding of the molecular mechanisms
underlying these diverse RIP4 functions, and to uncover how
RIP4 interacts with other pathways regulating epidermal
differentiation or inflammation.
MATERIALS AND METHODS
Plasmid construction
Plasmid pHR2 containing the human keratin 14 (K14) promoter was
a kind gift of Sabine Werner (Zurich, Switzerland) (Vassar et al.,
1989; Munz et al., 1999). The unique Sma1 cloning site for cDNA
insertion was converted to an Fse1/Pme1/Asc1 polylinker to create
pHB137-9. Mouse RIP4 (GenBank accession number AF302127)
was used as a template for the PCR to generate the open reading
frame (50–2,410 in mouse RIP4) flanked by a 50-Fse1 site and a
consensus translation initiation sequence, and a 30-Asc1 site directly
after the stop codon. This fragment was inserted in pHB137-9
digested with Fse1/Asc1 to yield pHB151-6. Nucleotide sequencing
confirmed that the PCR fragment was identical to the template
sequence. The K14/mouse RIP4/human growth hormone (hGH)
polyA expression cassette was excised from pHB151-6 with Kpn1, to
eliminate bacterial sequences from the microinjection fragment.
Mouse strains
To generate K14-RIP4 mice, the Kpn1 fragment of pHB151-6 was
microinjected at a concentration of 2 ng ml1 in 10mM of Tris and
0.1mM of EDTA (pH 8.0) into the pronuclei of B6D2F2 mouse
embryos (Taconic, Germantown, NY), and implanted into pseudo-
pregnant Swiss Webster recipients (Taconic). Mice were genotyped
by PCR with primers in the hGH polyA region to screen for founders.
Transgenic expressers were determined using quantitative reverse
transcription-PCR analysis of tail skin biopsies from founders. Total
tail skin RNA was isolated using the RNeasy Midi Kit (Qiagen,
Valencia, CA). Reverse transcription-PCR was carried out using a
TaqMan Reverse Transcription Reagents kit (Applied Biosystems,
Foster City, CA). Expression levels were determined by the
expression of an hGH probe (Amgen, Seattle, WA) or murine RIP4
probe (Amgen) relative to an hypoxanthine phosphoribosyl transfer-
ase housekeeper gene (Applied Biosystems). The highest expressers
were developed into lines by backcrossing to C57BL/6 mice
(Taconic).
Before using in the skin cancer model, K14-RIP4 mice were
backcrossed to FVB/N mice (Taconic) using Marker-Assisted
Accelerated Backcrossing (Charles River Laboratories, Wilmington,
MA) and were found to be at least 99.5% FVB/N mice.
TNFR1-, IKKa-, and RIP4-deficient mice are maintained on
C57BL/6 backgrounds and have been described earlier (Peschon
et al., 1998; Takeda et al., 1999; Holland et al., 2002). SfnEr/þ mice
were maintained on a mixed C57BL/6 and CBA background (Jackson
Laboratory, Bar Harbor, ME).
Immunohistochemistry
For histopathological examination, cross-sectioned embryos or
tissues were fixed in zinc fixative (K14-RIP4; RIP4/), zinc-buffered
formalin (Z-fix, Anatech, Battle Creek, MI) (K14-RIP4; IKKa/), or
10% neutral buffered formalin (K14-RIP4; SfnEr/Er, K14-RIP4 mice
used in inflammation studies), and then paraffin embedded. Sections
4mm thick were stained with hematoxylin and eosin (H&E) or with
antibodies for immunohistochemical detection of proteins. Staining
was primarily carried out by Phenopath Laboratories (Seattle, WA)
using an autostainer (Dako, Carpinteria, CA). After antigen retrieval
in 10mM of citrate buffer (pH 6), primary antibodies were detected
with horseradish peroxidase-polymer-conjugated secondary antibo-
dies using Dako EnVisionþ (RIP4 antibody), or biotinylated
secondary antibody using Elite ABC peroxidase (all other antibodies,
Vector Laboratories, Burlingame, CA). Signal was developed in
Dako DABþ and counterstained with Mayer’s hematoxylin.
Immunostaining of murine RIP4 used polyclonal antibodies from
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rabbits immunized with a KLH-conjugated peptide of the sequence
GCGQENIVRTLLRRGVDVGLQGKD. Specific antibodies were col-
umn-purified using protein A and then the RIP4 peptide. Other
primary antibodies used were K1 (Covance, Princeton, NJ, AF109),
K6 (Covance, cat. no. PRB-169P), K14 (Covance, AF64), involucrin
(Covance, cat. no. PRB-142C), stratifin (Santa Cruz Biotechnology,
Santa Cruz, CA, C-18), and IKKa (Cell Signaling Technology,
Beverly, MA, #2682). Under the conditions used, no stratifin or
IKKa protein was detectable in SfnEr/Er or IKKa/ skin, respectively
(data not shown).
Animal models
For TPA-mediated ear inflammation assays, 20 ml of 50 mgml1 TPA
(Sigma-Aldrich, St Louis, MO) in ethanol was applied using a pipette
to the right ears of anesthetized mice, and 20 ml of ethanol was
applied to the left. Ear thickness was measured on anesthetized mice
using a dial thickness gauge (Mitutoyo America Corporation, Aurora,
IL). Increase in ear thickness was calculated by subtracting baseline
thickness from subsequent measurements. A log transformation was
applied to the data to ensure normality. Statistical significance was
evaluated using a repeated measure model for the overall effect and
analysis of variance for each time point.
To assay contact hypersensitivity, the back skin of anesthetized
mice was shaved, and 25 ml of 0.5% DNFB (Sigma-Aldrich) in
acetone/olive oil (4:1) was applied to the skin using a pipette. Five
days later, ear thickness was measured, and 10 ml of 0.25% DNFB
was applied to the inner surface of the right ear, or 10 ml of vehicle to
the left ear. Increase in ear thickness and statistical significance was
evaluated as above.
For the DMBA/TPA skin carcinogenesis model, tumors were
initiated on the shaved back skin of 7- to 8-week-old mice with
25 mg of DMBA (Sigma-Aldrich) in 0.2ml of acetone on week 0,
followed by twice weekly promotion with 5 mg of TPA in 0.2ml
acetone for 20 weeks. Mice were scored weekly, and were killed
30 weeks after DMBA application or earlier if they showed signs
of lethargy or distress. To quantify intracorneal pustules, animals
were treated bi-weekly with TPA for 2 weeks, and three strips of
skin were collected from each animal 18 hours after the final TPA
treatment. The number of pustules observed in 4-mm-thick H&E-
stained sections of skin was divided by the total length of skin
sectioned to yield the number of pustules per centimeter. After
14 weeks of TPA treatment to animals enrolled in the DMBA/TPA
model, three strips of skin were collected and sectioned from
each animal, and epidermal hyperplasia was scored blindly on a
4-point graded scale. The Wilcoxon–Mann–Whitney test was used
to evaluate statistical significance.
All protocols used in these studies were in compliance with
federal guidelines and approved by the Amgen Institutional Animal
Care and Use Committee (IACUC).
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